|
1
|
Binsalamah ZM, Paul A, Prakash S and
Shum-Tim D: Nanomedicine in cardiovascular therapy: recent
advancements. Expert Rev Cardiovasc Ther. 10:805–815. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dhalla NS, Rangi S, Babick AP, Zieroth S
and Elimban V: Cardiac remodeling and subcellular defects in heart
failure due to myocardial infarction and aging. Heart Fail Rev.
17:671–681. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nagai T and Komuro I: Gene and cytokine
therapy for heart failure: molecular mechanisms in the improvement
of cardiac function. Am J Physiol Heart Circ Physiol.
303:H501–H512. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Timmers L, Sluijter JP, van Keulen JK, et
al: Toll-like receptor 4 mediates maladaptive left ventricular
remodeling and impairs cardiac function after myocardial
infarction. Circ Res. 102:257–264. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tao ZY, Cavasin MA, Yang F, Liu YH and
Yang XP: Temporal changes in matrix metalloproteinase expression
and inflammatory response associated with cardiac rupture after
myocardial infarction in mice. Life Sci. 74:1561–1572. 2004.
View Article : Google Scholar
|
|
6
|
de Faire U and Frostegård J: Natural
antibodies against phosphorylcholine in cardiovascular disease. Ann
NY Acad Sci. 1173:292–300. 2009.PubMed/NCBI
|
|
7
|
Sun M, Dawood F, Wen WH, et al: Excessive
tumor necrosis factor activation after infarction contributes to
susceptibility of myocardial rupture and left ventricular
dysfunction. Circulation. 110:3221–3228. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Turner NA: Therapeutic regulation of
cardiac fibroblast function: targeting stress-activated protein
kinase pathways. Future Cardiol. 7:673–691. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Taube A, Schlich R, Sell H, Eckardt K and
Eckel J: Inflammation and metabolic dysfunction: links to
cardiovascular diseases. Am J Physiol Heart Circ Physiol.
302:H2148–H2165. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kunes P, Holubcova Z, Kolackova M and
Krejsek J: Interleukin-33, a novel member of the IL-1/IL-18
cytokine family, in cardiology and cardiac surgery. Thorac
Cardiovasc Surg. 58:443–449. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Milovanovic M, Volarevic V, Radosavljevic
G, et al: IL-33/ST2 axis in inflammation and immunopathology.
Immunol Res. 52:89–99. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ohno T, Morita H, Arae K, Matsumoto K and
Nakae S: Interleukin-33 in allergy. Allergy. 67:1203–1214. 2012.
View Article : Google Scholar
|
|
13
|
Miller AM, Xu D, Asquith DL, et al: IL-33
reduces the development of atherosclerosis. J Exp Med. 205:339–346.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Krishnamurthy P, Subramanian V, Singh M
and Singh K: Deficiency of beta1 integrins results in increased
myocardial dysfunction after myocardial infarction. Heart.
92:1309–1315. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hayashidani S, Tsutsui H, Ikeuchi M, et
al: Targeted deletion of MMP-2 attenuates early LV rupture and late
remodeling after experimental myocardial infarction. Am J Physiol
Heart Circ Physiol. 285:H1229–H1235. 2003.PubMed/NCBI
|
|
16
|
Subramanian V, Krishnamurthy P, Singh K
and Singh M: Lack of osteopontin improves cardiac function in
streptozotocin-induced diabetic mice. Am J Physiol Heart Circ
Physiol. 292:H673–H683. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ii M, Nishimura H, Iwakura A, et al:
Endothelial progenitor cells are rapidly recruited to myocardium
and mediate protective effect of ischemic preconditioning via
‘imported’ nitric oxide synthase activity. Circulation.
111:1114–1120. 2005.PubMed/NCBI
|
|
18
|
Paulus WJ: Cytokines and heart failure.
Heart Fail Monit. 1:50–56. 2000.
|
|
19
|
McKinsey TA: Targeting inflammation in
heart failure with histone deacetylase inhibitors. Mol Med.
17:434–441. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rui T, Zhang J, Xu X, Yao Y, Kao R and
Martin CM: Reduction in IL-33 expression exaggerates
ischaemia/reperfusion-induced myocardial injury in mice with
diabetes mellitus. Cardiovasc Res. 94:370–378. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang HF, Xie SL, Chen YX, et al: Altered
serum levels of IL-33 in patients with advanced systolic chronic
heart failure: correlation with oxidative stress. J Transl Med.
10:1202012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Aukrust P, Yndestad A, Damås JK and
Gullestad L: Inflammation and chronic heart failure-potential
therapeutic role of intravenous immunoglobulin. Autoimmun Rev.
3:221–227. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Suzuki K, Murtuza B, Smolenski RT, et al:
Overexpression of interleukin-1 receptor antagonist provides
cardioprotection against ischemia-reperfusion injury associated
with reduction in apoptosis. Circulation. 104:I308–I313. 2001.
View Article : Google Scholar
|
|
24
|
Wang M, Tsai BM, Turrentine MW, Mahomed Y,
Brown JW and Meldrum DR: p38 mitogen activated protein kinase
mediates both death signaling and functional depression in the
heart. Ann Thorac Surg. 80:2235–2241. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li Z, Ma JY, Kerr I, et al: Selective
inhibition of p38alpha MAPK improves cardiac function and reduces
myocardial apoptosis in rat model of myocardial injury. Am J
Physiol Heart Circ Physiol. 291:H1972–H1977. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ling H, Gray CB, Zambon AC, et al:
Ca2+/Calmodulin-dependent protein kinase II δ mediates
myocardial ischemia/reperfusion injury through nuclear factor-κB.
Circ Res. 112:935–944. 2013.
|
|
27
|
Kim YS, Kim JS, Kwon JS, et al: BAY
11-7082, a nuclear factor-κB inhibitor, reduces inflammation and
apoptosis in a rat cardiac ischemia-reperfusion injury model. Int
Heart J. 51:348–353. 2010.
|
